Changes in scores of disease activity by DAS28-ESR, functional status and disability by Health Assessment Questionnaire (HAQ-DI), and fatigue by FACIT-Fatigue Scale (FFS) in 15 patients with active rheumatoid arthritis from baseline through 6 months of treatment with tocilizumab (8 mg/kg). Data are mean ± SD.
| Baseline | 1st Month | 2nd Month | 3rd Month | 6th Month | p* | |
|---|---|---|---|---|---|---|
| DAS28 | 5.77 ± 1.2 | 4.38 ± 0.88 | 3.6 ± 0.97 | 2.7 ± 0.88 | 2.5 ± 0.9 | < 0.00001 |
| HAQ-DI | 1.5 ± 0.8 | 1.1 ± 0.66 | 1 ± 0.58 | 0.9 ± 0.6 | 0.7 ± 0.6 | < 0.00001 |
| FFS | 20.3 ± 11 | 28.3 ± 11.3 | 33.7 ± 12 | 36.4 ± 10 | 38 ± 9.93 | < 0.00001 |
↵* Calculated by linear mixed models. DAS28-ESR: 28-joint Disease Activity Score-erythrocyte sedimentation rate; FACIT: Functional Assessment of Chronic Illness Therapy.